The Extraordinary General Meeting of ChronTech Pharma AB
The Extraordinary General Meeting of ChronTech Pharma AB was held in Stockholm on 19 August, 2011.
Election of Board of Directors
Dr John Climax, Dr Simon Kukes and Dr Prem Lachman were elected as members of the Board until the end of the next Annual General Meeting.
Approval of the resolution to subscribe a targeted new issue of shares
The Meeting resolved to approve the decision of the Board of Directors from July 26, 2011 to issue a maximum of 80.000.000 shares at a price of (rounded) 0.31 SEK per share with respect to the subscription of 10.000.000 shares by the Chairman of the Board Thomas Lynch.
Authorization to issue new shares
The Meeting resolved to authorize the Board to resolve, at one or more occasions prior to the next Annual General Meeting, to issue a maximum of 10.000.000 new shares. Payment shall be made through set-off of claims against the company. The purpose with the authorization is to enable ChronTech Pharma AB to convert a bridge financing loan of 500,000 USD to new shares. The new issue of shares shall be made with the same terms as the new issue of 80.000.000 shares.
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se
About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.